evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

60 questions · 63 findings · 6 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 3 · 4.8%GRADE not reported 0 · 0%Very low 8 · 12.7%Low 32 · 50.8%Moderate 14 · 22.2%High 6 · 9.5%

Artesunate vs placebo

Parasitological failure At 8 weeks · patients with treating urinary schistosomiasis

It is very uncertain whether artesunate changes parasitological failure At 8 weeks compared with placebo (very low certainty).

1 finding from 1 review

Artesunate vs placebo

Microhaematuria At 8 weeks · patients with treating urinary schistosomiasis

Artesunate showed no clear difference in microhaematuria At 8 weeks compared with placebo (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ)

Total failure: day 28 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 28 (PCR‐adjusted) compared with artesunate‐amodiaquine (AS‐AQ) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ)

Total failure: day 42 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 42 (PCR‐adjusted) compared with artesunate‐amodiaquine (AS‐AQ) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ)

Total failure: day 28 (unadjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) probably leads to lower total failure: day 28 (unadjusted) compared with artesunate‐amodiaquine (AS‐AQ) (moderate certainty).

2 findings from 1 review

Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ)

First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal ALT increase (42 days) compared with artesunate‐amodiaquine (AS‐AQ) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ)

First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria

It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal AST increase (42 days) compared with artesunate‐amodiaquine (AS‐AQ) (very low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ)

First treatment, abnormal bilirubin increase (42 days) · adults and children with uncomplicated P falciparum malaria

It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal bilirubin increase (42 days) compared with artesunate‐amodiaquine (AS‐AQ) (very low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

Total failure: day 28 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 28 (PCR‐adjusted) compared with mefloquine plus artesunate (MQ + AS) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

Total failure: day 42 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 42 (PCR‐adjusted) compared with mefloquine plus artesunate (MQ + AS) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

Total failure: day 28 (unadjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) probably leads to lower total failure: day 28 (unadjusted) compared with mefloquine plus artesunate (MQ + AS) (moderate certainty).

2 findings from 1 review

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

Serious adverse events (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in serious adverse events (42 days) compared with mefloquine plus artesunate (MQ + AS) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal ALT increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria

It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal AST increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (very low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

First treatment, abnormal bilirubin increase (42 days) · adults and children with uncomplicated P falciparum malaria

It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal bilirubin increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (very low certainty).

1 finding from 1 review